Perrigo Recalls Albuterol Sulfate Inhalers Due to Defective Delivery System
Perrigo is recalling 7.8 million Albuterol Sulfate inhalers nationwide because the delivery system may fail to dispense the medication.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves a risk-of-harm product (respiratory medication) where the delivery system failure could lead to inadequate treatment, though no specific injuries or illnesses are reported in the source text.
Plain-English summary
Perrigo Company PLC is recalling 7,775,813 units of Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, 200 metered inhalations. The product is manufactured by Catalent Pharma Solutions and distributed by Perrigo. The recall covers specific lot numbers with expiration dates ranging from September 2020 to June 2022, as detailed in the source metadata.
The recall was initiated due to a sustained trend of complaints regarding the defective delivery system's failure to dispense the medication. This defect may prevent patients from receiving the intended dose of albuterol, a bronchodilator used to treat or prevent wheezing and shortness of breath.
The affected inhalers were distributed nationwide in the U.S. Consumers should check their Albuterol Sulfate inhalers for the specific lot numbers and expiration dates listed in the recall notice. If the product matches the recalled lots, patients should stop using it and contact their healthcare provider or pharmacist for a replacement or alternative treatment.
The recalled product
- Product
- ALBUTEROL SULFATE (ALBUTEROL SULFATE)
- Brand
- ALBUTEROL SULFATE
- Manufacturer
- Perrigo Company PLC
- Category
- Drug — Inhalation Aerosol
- Affected units
- 7,775,813
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- 18MC-052
- 18MC-055
- 18MC-056
- 18MC-057
- 18MC-058
- 18MC-060
- EXP 09/2020
- 18MC-061
- 18MC-062
- 18MC-064
- 18MC-065
- 18MC-066
- 18MC-068
- 18MC-069
- 18MC-070
- 18MC-071
- 18MC-072
- 18MC-073
- 18MC-074 EXP 10/2020
- 18MC-075
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ALBUTEROL SULFATE
- ModerateAlbuterol inhalers recalled after failing stability specification for particle size distribution
FDA (Drugs) · 2025-08-27
- HighAlbuterol Sulfate Inhaler Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- ModerateAlbuterol sulfate inhalation aerosol recalled for temperature storage deviation
FDA (Drugs) · 2024-01-03
- CriticalPrescription albuterol inhalers recalled nationwide due to defective valve seals
FDA (Drugs) · 2023-07-19
- HighAlbuterol sulfate inhalation solution recalled for manufacturing temperature-abuse defect
FDA (Drugs) · 2022-06-15
Same manufacturer · Perrigo Company PLC
See all →- ModerateCareOne Severe Congestion Nasal Spray Recalled Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateEquate Children's Pain and Fever Acetaminophen Suspension Recall
FDA (Drugs) · 2022-03-02
- ModerateEqualine Nasal Oxymetazoline HCl Nasal Spray Recalled for Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateUP AND UP Childrens Acetaminophen Recall Due to Contaminated Excipient
FDA (Drugs) · 2022-03-02
- ModerateEquate Children's Pain and Fever recalled due to contaminated excipient
FDA (Drugs) · 2022-03-02
Same hazard · defective delivery system
See all →- ModerateCetrorelix injection kits recalled over missing or duplicated needles inside
FDA (Drugs) · 2026-02-18
- HighAIRSUPRA Albuterol and Budesonide Inhalation Aerosol Recalled for Defective Delivery System
FDA (Drugs) · 2025-05-28
- HighLorazepam Oral Syringes Recalled Due to Defective Delivery System Causing Leakage
FDA (Drugs) · 2025-03-12
- ModerateVarithena Administration Pack Recalled Due to Incorrect Syringe Connector Type
FDA (Drugs) · 2024-12-18
- HighDaytrana Methylphenidate Transdermal Patches Recalled for Defective Delivery System
FDA (Drugs) · 2023-03-29